SGLT2 inhibitors resulted in a significant reduction in total HF hospitalizations and cardiovascular death [rate ratio: 0.71 (0.61–0.84); P < 0.001; I2 = 0%]. The gene discussed is SLC5A2; the disease is hydrops fetalis.